Medical device regulatory articles
Practical insight for decisions that carry regulatory, clinical, and commercial consequences.
SHOTUNE publishes medical device regulatory articles for founders, executives, functional leaders, portfolio owners, and investment partners working through high-stakes MedTech decisions.
The goal is not to add more regulatory noise. Each article is written to help leadership understand how a pathway decision, clinical evidence gap, quality-system weakness, audit concern, or portfolio issue can affect approval timing, market continuity, diligence confidence, and enterprise value.
These articles connect technical decisions to the business consequences leadership must manage. They also explain where earlier senior judgment can reduce uncertainty before separate teams begin solving different versions of the same problem.
What the medical device regulatory articles cover
The SHOTUNE article library focuses on decisions that cross regulatory, clinical, quality, portfolio, and commercial boundaries.
Regulatory strategy and global submissions
Review pathway choices, FDA and EU MDR expectations, claims, regulator responses, global submissions, remediation decisions, and market-access risk. Explore regulatory strategy.
Clinical evidence and lifecycle planning
Understand how CER, CEP, PMCF, PMS, benefit-risk, claims, study architecture, and post-market obligations should support one defensible evidence position. Explore clinical evidence strategy.
Quality systems and compliance governance
Examine CAPA, design controls, risk management, inspection readiness, remediation, audit exposure, and the quality controls needed to support growth and market continuity. Explore quality management systems.
Portfolio governance and executive visibility
See how certificate timing, product continuity, evidence burden, resource allocation, and cross-functional ownership can create exposure across a medical device portfolio.
For longer executive resources, review the SHOTUNE Knowledge Series. New medical device regulatory articles will be added here as they are published.
New articles are being prepared. In the meantime, review the SHOTUNE Knowledge Series for executive-level guidance on EU MDR, evidence strategy, portfolio governance, and market continuity.
Need judgment on a live situation?
Reading can clarify the issue. A focused conversation can clarify the next decision. Request a confidential strategy discussion when regulatory, clinical, quality, or portfolio uncertainty is already affecting the business.